Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain
Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the
Knee
- Pain
Reductions Observed at Eight Weeks Sustained up to 12 Weeksand Drug Remains Very Well Tolerated - SOUTH SAN FRANCISCO, Calif., July 02, 2007/PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminarylonger-term, follow-up results from a Phase 2 study showing that a1mg treatment with Adlea(TM) (formerly 4975) in patients withmoderate-to-severe osteoarthritis of the knee prod...
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients
Final Results from Exploratory Phase IIa Clinical Trial in Type 2Diabetes Patients Announced TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - TransitionTherapeutics Inc. ("Transition") , today announces the results fromits exploratory Phase IIa clinical trial indicating that 4-weeks ofdaily treatments with gastrin-based therapy, E1-I.N.T.(TM), showedsustained
reductions in blood glucose co...
Byetta Treatment for Three and a Half Years Associated with
Reductions in Cardiovascular Risk Factors in People with Type 2
Diabetes
- BYETTA also Showed Sustained Improvements in Blood GlucoseControl and Progressive Weight Loss - CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. and Eli Lilly and Company today announcedresults from a study that showed BYETTA(R) (exenatide) injectionsustained improvements in blood sugar levels and progressive weightloss through three and a half years of thera...
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of
Improved Glycemic Control and Significant Reductions of
LDL-Cholesterol and C-Reactive Protein
Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B
Showed Significant Reductions in Disease Activity in Patients with
Active Systemic Lupus Erythematosus
-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...
More>>